Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) has successfully completed enrollment for its MAESTRO-NASH OUTCOMES trial, a ...

Oppenheimer lowered the firm’s price target on Madrigal Pharmaceuticals (MDGL) to $350 from $375 and keeps an Outperform rating on the ...

Oppenheimer analyst Jay Olson maintained a Buy rating on Madrigal Pharmaceuticals (MDGL – Research Report) today and set a price target of $350.00. The company’s shares closed yesterday at $203.59.

Patients with well-compensated NASH cirrhosis and three metabolic risk factors were selected for inclusion in the study.

Cantor Fitzgerald reiterated their neutral rating on shares of Madrigal Pharmaceuticals (NASDAQ:MDGL – Free Report) in a ...

In this article, we are going to take a look at where Madrigal Pharmaceuticals (NASDAQ:MDGL) stands against other biggest stocks with negative beta to consider. Beta is a measureament of market ...

The road to the development of treatments for non-alcoholic steatohepatitis (NASH) is littered with failed projects, but US biotech Madrigal Pharma thinks it now has enough evidence for its drug ...

Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) is a biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH), a liver disease with high unmet medical need.

As of June 30, 2024, Paulson held 1.85 million shares of Madrigal Pharmaceuticals, which would currently be worth around $386 million as of the time of writing. This position is a significant one ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Detailed price information for Madrigal Pharmaceuticals Inc (MDGL-Q) from The Globe and Mail including charting and trades.